Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ENFORTUMAB VEDOTIN-EJFV Cause Neoplasm progression? 15 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 15 reports of Neoplasm progression have been filed in association with ENFORTUMAB VEDOTIN-EJFV. This represents 0.4% of all adverse event reports for ENFORTUMAB VEDOTIN-EJFV.

15
Reports of Neoplasm progression with ENFORTUMAB VEDOTIN-EJFV
0.4%
of all ENFORTUMAB VEDOTIN-EJFV reports
1
Deaths
5
Hospitalizations

How Dangerous Is Neoplasm progression From ENFORTUMAB VEDOTIN-EJFV?

Of the 15 reports, 1 (6.7%) resulted in death, 5 (33.3%) required hospitalization.

Is Neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ENFORTUMAB VEDOTIN-EJFV. However, 15 reports have been filed with the FAERS database.

What Other Side Effects Does ENFORTUMAB VEDOTIN-EJFV Cause?

Rash (560) Malignant neoplasm progression (410) Neuropathy peripheral (410) Fatigue (281) Pruritus (260) Diarrhoea (257) Death (238) Decreased appetite (230) Off label use (193) Alopecia (185)

What Other Drugs Cause Neoplasm progression?

PALBOCICLIB (10,885) SUNITINIB MALATE (1,920) CYCLOPHOSPHAMIDE (1,588) CARBOPLATIN (1,370) AXITINIB (1,315) DOXORUBICIN (1,276) LETROZOLE (1,225) PACLITAXEL (1,180) CRIZOTINIB (1,161) VINCRISTINE (1,106)

Which ENFORTUMAB VEDOTIN-EJFV Alternatives Have Lower Neoplasm progression Risk?

ENFORTUMAB VEDOTIN-EJFV vs ENFORTUMAB VEDOTIN\ENFORTUMAB VEDOTIN-EJFV ENFORTUMAB VEDOTIN-EJFV vs ENFUVIRTIDE ENFORTUMAB VEDOTIN-EJFV vs ENOXAPARIN ENFORTUMAB VEDOTIN-EJFV vs ENOXAPARIN - WINTHROP ENFORTUMAB VEDOTIN-EJFV vs ENSIFENTRINE

Related Pages

ENFORTUMAB VEDOTIN-EJFV Full Profile All Neoplasm progression Reports All Drugs Causing Neoplasm progression ENFORTUMAB VEDOTIN-EJFV Demographics